Drug intelligence / Profile preview

ciprofloxacin + trimethoprim + sulfamethoxazole + ertapenem

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral, Intravenous, Intramuscular
01

Overview

This is a combination of four antibiotics used for treating various bacterial infections: - **Ciprofloxacin**: A fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication. - **Trimethoprim**: An antifolate medication that inhibits dihydrofolate reductase, interfering with bacterial folate synthesis. - **Sulfamethoxazole**: A sulfonamide antibiotic that inhibits dihydropteroate synthase, also interfering with bacterial folate synthesis. Often used in combination with trimethoprim (as co-trimoxazole or TMP-SMX). - **Ertapenem**: A carbapenem antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins. This combination would provide extremely broad-spectrum coverage against Gram-positive, Gram-negative, and anaerobic bacteria, including many drug-resistant strains. It would typically be used for severe, complex, or polymicrobial infections.

02

Targets

DHFR (Dihydrofolate reductase)Topo IV (Bacterial Topoisomerase IV)DHPS (Dihydropteroate synthase)DNA gyrasePBP (Penicillin-binding protein family)

Beyond the preview

Go deeper on ciprofloxacin + trimethoprim + sulfamethoxazole + ertapenem.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ciprofloxacin + trimethoprim + sulfamethoxazole + ertapenem.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call